Trial Profile

A Phase I first in human study of ATG-201

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATG 201 (Primary)
Indications Autoimmune disorders; B-cell lymphoma
Focus First in man; Therapeutic Use

Most Recent Events

19 Mar 2026 New trial record
03 Mar 2026 According to a UCB media release, the Antengene plans to submit clinical trial applications for ATG-201 in China and Australia in the first quarter of 2026. Antengene will complete first-in-human phase 1 studies in these two jurisdictions and thereafter transfer further ATG-201 clinical and other development to UCB.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com